Skip header and navigation

Narrow By

   MORE

100 records – page 1 of 5.

Advances in DNA repair in cancer therapy

https://libcat.nshealth.ca/en/permalink/provcat32399
Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors. --New York, NY: Springer , c2013.
Available Online
View e-Book
Location
Online
This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and dow…
Available Online
View e-Book
Other Authors
Panasci, Lawrence
Aloyz, Raquel
Alaoui-Jamali, Moulay
Responsibility
Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2013
Physical Description
1 online resource (viii, 312 p. : 35 ill., 25 ill. in color)
Series Vol.
72
Series Title
Cancer drug discovery and development
ISBN
9781461447412
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
DNA Repair
Neoplasms - drug therapy
Neoplasms - genetics
Subjects (LCSH)
Oncology
Abstract
This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling is examined.
Contents
Repair of DNA interstrand cross-links produced by cancer chemotherapeutic drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- Relationship between DNA-repair genes, cellular radiosensitivity, and the response of tumors annd normal tissues to radiotherapy -- Important roles of ERCCI in DNA repair and targeted therapy -- The role of BRCA1 and BRCA2 in anticancer drug therepy -- DNA-PK in CLL chemotherapy -- Poly (ADP) ribose polymerase at the interface of DNA damage signaling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a therapeutic target -- Telomores, Telomerase, and DNA damage response in cancer therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index.
Format
e-Book
Location
Online
Less detail

Advances in peritoneal surface oncology

https://libcat.nshealth.ca/en/permalink/provcat30092
--Berlin, Heidelberg: Springer-Verlag , c2007.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Other Authors
González-Moreno, Santiago
Place of Publication
Berlin, Heidelberg
Publisher
Springer-Verlag
Date of Publication
c2007
Series Vol.
169
Series Title
Resent results in cancer research
ISBN
9783540307600
Subjects (MeSH)
Carcinoma - therapy
Mesothelioma - therapy
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - surgery
Subjects (LCSH)
Oncology
Abdomen - Surgery
Format
e-Book
Location
Online
Less detail

Angiogenesis inhibition

https://libcat.nshealth.ca/en/permalink/provcat28492
--Berlin, Heidelberg: Springer-Verlag , c2010.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Other Authors
Liersch, Rüdiger
Berdel, Wolfgang E
Kessler, Torsten
Place of Publication
Berlin, Heidelberg
Publisher
Springer-Verlag
Date of Publication
c2010
Series Vol.
180
Series Title
Recent results in cancer research
ISBN
9783540782810
Subjects (MeSH)
Angiogenesis Inhibitors
Neoplasms - drug therapy
Neovascularization, pathologic - drug therapy
Subjects (LCSH)
Oncology
Hematology
Format
e-Book
Location
Online
Less detail

Antiangiogenic Agents in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat40632
edited by Beverly A. Teicher, Lee M. Ellis. (2nd ed.) --Totowa, NJ: Humana Press , c2008.
Available Online
View e-Book
Location
Online
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art…
Available Online
View e-Book
Other Authors
Teicher, Beverly A
Ellis, Lee M
Responsibility
edited by Beverly A. Teicher, Lee M. Ellis
Edition
2nd ed.
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2008
Physical Description
1 online resource (xviii, 559 p. : ill.)
Series Title
Cancer drug discovery and development
ISBN
9781597451840
9781588298706 (print ed.)
Subjects (MeSH)
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - therapeutic use
Neoplasms - drug therapy
Neovascularization, pathologic - drug therapy
Abstract
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
Contents
Part I. Basic Biology of Angiogenesis -- Vascular Endothelial Growth Factor Family and Its Receptors -- The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors -- The Role of Integrins in Tumor Angiogenesis -- Tumor Endothelial Cell Abnormalities -- The Extracellular Matrix and VEGF Processing -- Endothelial Precursor Cells -- Role of Pericytes in Angiogenesis -- Newer Vascular Targets -- Chemokines in Angiogenesis -- Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis -- Imaging Angiogenesis -- Tumor Blood Vessels -- Lymphatic System in the Pathology of Cancer -- Part II. Translational Research in Tumor Angiogenesis -- VEGF in the Adult -- Normalization of Tumor Vasculature and Microenvironment -- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man -- Small-Molecule Vascular Disrupting Agents in Cancer Therapy -- Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents -- Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside -- Regulation of Angiogenesis in Cancer and Its Therapeutic Implications -- Part III. Antiangiogenic Therapy in the Clinical Trial Results and Future Directions -- Angiogenesis and Angiogenesis Inhibition in Sarcomas -- Antiangiogenesis Agents in Colorectal Cancer -- Antiangiogenic Therapy for Primary CNS Tumors -- Angiogenesis Inhibitors for the Treatment of Lung Cancer -- Antiangiogenic Therapy of Renal Cell Carcinoma -- Antiangiogenesis Therapies in Gynecologic Malignancies -- Antiangiogenic Agents in Myeloid Malignancies -- Angiogenesis in Malignant and Non-Malignant Pediatric Tumors -- Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis -- Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials -- The Role of Imaging in the Clinical Development of Antiangiogenic Agents.
Format
e-Book
Location
Online
Less detail

Antibody-drug conjugates and immunotoxins : from pre-clinical development to therapeutic applications

https://libcat.nshealth.ca/en/permalink/provcat32428
Gail Lewis Phillips, editor. --New York, NY: Springer , c2013.
Available Online
View e-Book
Location
Online
The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under int…
Available Online
View e-Book
Other Authors
Phillips, Gail Lewis
Responsibility
Gail Lewis Phillips, editor
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2013
Physical Description
1 online resource (ix, 372 p. : 88 ill., 45 ill. in color)
Series Title
Cancer drug discovery and development
ISBN
9781461454564
Subjects (MeSH)
Antibodies
Drug Combinations
Immunotoxins - therapeutic use
Neoplasms - drug therapy
Subjects (LCSH)
Oncology
Monoclonal antibodies
Abstract
The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
Contents
Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins -- Antibody-Drug Conjugate Development -- Components of ADC Development: Assay Methodologies and Challenges -- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates -- Predictive Biomarkers for Antibody-Drug Conjugates -- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates -- Linker Technology and Impact of Linker Design on ADC Properties -- Antibody-drug conjugates for the treatment of B-cell malignancies -- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies -- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies -- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer -- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) -- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer -- EphA2 Immunoconjugate -- Anti-PSMA Antibody-Drug Conjugates -- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine -- Studies on the Metabolism of Antibody-Drug Conjugates -- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu -- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors -- Index
Format
e-Book
Location
Online
Less detail

Apoptosis, Senescence, and Cancer

https://libcat.nshealth.ca/en/permalink/provcat29394
edited by David A. Gewirtz, Shawn E. Holt, Steven Grant. (2nd ed.) --Totowa, NJ: Humana Press , c2007.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Gewirtz, David A
Other Authors
Holt, Shawn E
Grant, Steven
Responsibility
edited by David A. Gewirtz, Shawn E. Holt, Steven Grant
Edition
2nd ed.
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2007
Series Title
Cancer drug discovery and development
ISBN
9781597452212
Subjects (MeSH)
Apoptosis
Cell Aging - drug effects
Cell Transformation, Neoplastic
Neoplasms - drug therapy
Subjects (LCSH)
Oncology
Cytology
Format
e-Book
Location
Online
Less detail

Camptothecins in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat28891
edited by Val R. Adams, Thomas G. Burke. --Totowa, NJ: Humana Press , c2005.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Adams, Val R
Other Authors
Burke, Thomas G
Responsibility
edited by Val R. Adams, Thomas G. Burke
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2005
Series Title
Cancer drug discovery and development
ISBN
9781592598663
Subjects (MeSH)
Camptothecin - pharmacology
Camptothecin - therapeutic use
Neoplasms - drug therapy
Antineoplastic Agents, Phytogenic - therapeutic use
Subjects (LCSH)
Oncology
Pharmacy
Format
e-Book
Location
Online
Less detail

Cancer Chemotherapy in Clinical Practice

https://libcat.nshealth.ca/en/permalink/provcat30817
Terry Priestman. (2nd ed.) --London: Springer , c2012.
Available Online
View e-Book
Location
Online
The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses a…
Available Online
View e-Book
Author
Priestman, Terrence
Responsibility
Terry Priestman
Edition
2nd ed.
Place of Publication
London
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (xiii, 177 p. : 15 ill., 3 ill. in color)
ISBN
9780857297273
Subjects (MeSH)
Neoplasms - drug therapy
Antineoplastic Agents - therapeutic use
Subjects (LCSH)
Oncology
Pharmacy
Abstract
The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses and medical students, Cancer Chemotherapy in Clinical Practice is divided into three sections: The Theoretical Basis of Cancer Chemotherapy: following a historical introduction the different treatment modalities are explained in the context of basic tumor biology Practical Aspects of Chemotherapy: covering dosing and drug delivery together with an extensive discussion of possible side-effects and their management Chemotherapy in the Management of Cancer: explaining the place of drug treatment and the outcomes that can be expected from chemotherapy in all the major cancers.
Contents
1. The Theoretical Basis of Cancer Chemotherapy -- 2. Practical aspects of chemotherapy -- 3. Part III: Chemotherapy in the management of cancer
Format
e-Book
Location
Online
Less detail

Cancer Management in Man : Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures

https://libcat.nshealth.ca/en/permalink/provcat28897
edited by Boris R. Minev. --Dordrecht ; New York: Springer Science+Business Media , c2011.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Minev, Boris R
Responsibility
edited by Boris R. Minev
Place of Publication
Dordrecht ; New York
Publisher
Springer Science+Business Media
Date of Publication
c2011
Series Vol.
13
Series Title
Cancer growth and progression
ISBN
9789048197040
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Neoplasms - drug therapy
Neoplasms - therapy
Subjects (LCSH)
Oncology
Format
e-Book
Location
Online
Less detail

Cancer treatment and the ovary

https://libcat.nshealth.ca/en/permalink/provcat43596
Anderson, Richard. (1st ed.) --Amsterdam: Elsevier/Academic Press , 2015.
Access
Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
Location
Online
Author
Anderson, Richard
Edition
1st ed.
Place of Publication
Amsterdam
Publisher
Elsevier/Academic Press
Date of Publication
2015
Physical Description
online resource
ISBN
9780128015919
Subjects (MeSH)
Neoplasms - drug therapy
Ovary - drug effects
Access
Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
Format
e-Book
Location
Online
Less detail

Cancer treatment and the ovary : clinical and laboratory analysis of ovarian toxicity

https://libcat.nshealth.ca/en/permalink/provcat38860
edited by Richard A. Anderson, Norah Spears. --London, UK: Elsevier , c2015.
Available Online
View e-Book
Access
Registration required for PDF access.
Location
Online
Available Online
View e-Book
Other Authors
Anderson, Richard A
Responsibility
edited by Richard A. Anderson, Norah Spears
Alternate Title
Cancer treatment & the ovary
Place of Publication
London, UK
Publisher
Elsevier
Date of Publication
c2015
Physical Description
1 online resource, 149 p.
ISBN
9780128015919
Subjects (MeSH)
Neoplasms - drug therapy
Ovary - drug effects
Access
Registration required for PDF access.
Format
e-Book
Location
Online
Less detail

Cardio-Oncology : The Clinical Overlap of Cancer and Heart Disease

https://libcat.nshealth.ca/en/permalink/provcat41453
Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors. --Cham: Springer , 2017.
Available Online
View e-Book
Location
Online
Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist a…
Available Online
View e-Book
Other Authors
Kimmick, Gretchen G
Lenihan, Daniel J
Sawyer, Douglas B
Mayer, Erica L
Hershman, Dawn L
Responsibility
Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
2017
Physical Description
1 online resource (xv, 319 pages) : 55 illus., 49 illus. in color
ISBN
9783319430966
9783319430942 (print ed.)
Subjects (MeSH)
Antineoplastic Agents - adverse effects
Cardiotoxicity - complications
Cardiovascular Diseases - complications
Cardiovascular Diseases - prevention & control
Neoplasms - complications
Neoplasms - drug therapy
Abstract
Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.
Contents
1. Epidemiology of Cardio-Oncology -- 2. Cardiotoxicity of Anticancer Therapies -- 3. Screening and Monitoring for Cardiotoxicity During Cancer Treatment -- 4. Management of Chemotherapy-Associated Cardiomyopathy -- 5. Treatment of Hypertension in Patients Receiving Cancer Therapy -- 6. Preoperative and Pre-transplant Cardiac Evaluation in the Cancer Patient -- 7. Radiation Therapy and Cardiotoxicity -- 8. Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia -- 9. Vascular Complications of Cancer and Cancer Therapy -- 10. Breast Cancer Cardio-Oncology -- 11. Cardiac Toxic Chemotherapy and Cancer Survivorship -- 12. Geriatric Cardio-oncology -- 13. Future Clinical and Professional Directions in Cardio-oncology.
Format
e-Book
Location
Online
Less detail

Checkpoint Controls and Targets in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat29742
edited by Zahid H. Siddik. --Totowa, NJ: Humana Press , c2009.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Siddik, Zahid H
Responsibility
edited by Zahid H. Siddik
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2009
Series Title
Cancer drug discovery and development
ISBN
9781607611783
Subjects (MeSH)
Antineoplastic Agents - pharmacology
Cell Cycle Checkpoints
Cell Cycle - drug effects
Neoplasms - drug therapy
Format
e-Book
Location
Online
Less detail

Chemotherapy and biotherapy guidelines and recommendations for practice

https://libcat.nshealth.ca/en/permalink/provcat40858
Polovich, Martha. Oncology Nursing Society. --Pittsburgh, PA: Oncology Nursing Society , c2014.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Polovich, Martha
Corporate Author
Oncology Nursing Society
Other Authors
Olsen, MiKaela M.
LeFebvre, Kristine B.
Place of Publication
Pittsburgh, PA
Publisher
Oncology Nursing Society
Date of Publication
c2014
Physical Description
473 p.
ISBN
9781935864332
Subjects (MeSH)
Neoplasms - drug therapy - Outlines
Neoplasms - drug therapy - Practice Guideline
Format
e-Book
Location
Online
Less detail

Chemotherapy and Immunotherapy in Urologic Oncology : A Guide for the Advanced Practice Provider

https://libcat.nshealth.ca/en/permalink/provcat46364
Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors. --Cham: Springer , c2021.
Available Online
View e-Book
Access
NEW Springer 2021
Location
Online
This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current…
Available Online
View e-Book
Other Authors
Trabulsi, Edouard J.
Lallas, Costas D.
Lizardi-Calvaresi, Anne E.
Responsibility
Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2021
Physical Description
1 online resource (xiv, 307 p.) : 22 illus., 19 illus. in color
ISBN
9783030520212
9783030520205 (Print ed.)
9783030520229 (Print ed.)
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Urologic Neoplasms - drug therapy
Immunotherapy - methods
Specialty
Medical Oncology
Pharmacology
Regenerative Medicine
Urology
Abstract
This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects. .
Contents
Introduction: Integration of APP into Urologic Oncology Practice -- Part I. Prostate Cancer -- Overview and Active Surveillance of Prostate Cancer -- Monitoring and Managing Men Following Initial Treatment of Prostate Cancer -- Radical Prostatectomy and Survivorship after Radical Prostatectomy -- Multimodal Treatment Plans in Prostate Cancer -- Radiotherapy for Prostate Cancer -- Androgen Deprivation Treatment -- Second Generation Androgen Targeted Agents -- Chemotherapy and prostate cancer -- Radiopharmaceuticals for Prostate Cancer -- Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer -- Part II. Bladder Cancer -- Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis -- Intravesical Therapy for Non Muscle Invasive Urothelial Carcinoma -- Bladder Cancer: Muscle Invasive Disease, Neoadjuvant Chemotherapy, and Radical Cystectomy -- Chemoradiation Bladder Preservation -- Metastatic Bladder Cancer and the Use of Cisplatin Chemotherapy -- Immunotherapy for Metastatic Urothelial Cancer -- Novel and experimental Strategies in the Treatment of Metastatic Urothelial Carcinoma -- Upper Tract Urothelial Carcinoma -- Part III. Kidney Cancer -- Kidney Cancer and Its Treatment -- Targeted Therapies for Treatment of Metastatic Renal Cell Carcinoma -- Immune Therapies for Metastatic Kidney Cancer -- Novel Therapies for Renal Cell Carcinoma -- Part IV. Other Malignancies -- Testicular Cancer -- Penile Cancer.
Access
NEW Springer 2021
Format
e-Book
Location
Online
Less detail

Chemotherapy in Neonates and Infants : Pharmacological Oncology for Children Under 1 Year Old

https://libcat.nshealth.ca/en/permalink/provcat42571
Carolina Witchmichen Penteado Schmidt. --Cham: Springer , c2018.
Available Online
View e-Book
Location
Online
This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, e…
Available Online
View e-Book
Author
Penteado Schmidt, Carolina Witchmichen
Responsibility
Carolina Witchmichen Penteado Schmidt
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xix, 198 p.) : 8 illus. in color
ISBN
9783319705910
9783319705903 (print ed.)
9783319705927 (print ed.)
Subjects (MeSH)
Antineoplastic Agents - pharmacology
Drug-Related Side Effects and Adverse Reactions - prevention & control
Infant
Infant, Newborn
Neoplasms - drug therapy
Specialty
Medical Oncology
Pediatrics
Pharmacology
Abstract
This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, excretion, toxicity, drugs that can be used for each week or month of the patient's life, dose adjustment and treatment protocols. Chemotherapy in Neonates and Infants focuses on the safe treatment of children in the first year of life, and is aimed at pediatric oncology/hematology institutions, clinics and departments. It is particularly valuable for researchers, pediatric oncology physicians, pediatric and neonatology physicians, oncology pharmacists and the other healthcare professionals directly involved in the chemotherapy of neonates and infants.
Contents
1. Introduction -- 2. Protocols Used in Chemotherapy Treatment of Neonates and Infants -- 3. Pharmacokinetics and Pharmacodynamics of Chemotherapy Drugs in Neonates and Infants -- 4. Peculiarities of Most Commonly Used Chemotherapy Drugs in Neonates and Infants -- 5. Adjuvant Drugs Used in Chemotherapy for Neonates and Infants -- 6. Drug Interactions in Neonates and Infants -- 7. Toxicity -- 8. Tumor Lysis in Neonates and Infants -- 9. Chemotherapy in Neonates and Infants with Cancer and Other Congenital Diseases: Down Syndrome and HIV -- 10. Stem Cell Transplantation in Neonates and Infants.
Format
e-Book
Location
Online
Less detail

Colorectal cancer : evidence-based chemotherapy strategies

https://libcat.nshealth.ca/en/permalink/provcat22485
Saltz, Leonard B. --Totowa, NJ: Humana Press , 2007.
Call Number
WI 529 C719 2007
Location
Dickson Building
Call Number
WI 529 C719 2007
Author
Saltz, Leonard B
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
2007
Physical Description
292 p.
Series Title
Current clinical oncology
ISBN
1588297519
Subjects (MeSH)
Colorectal Neoplasms - drug therapy
Evidence-Based Medicine
Format
Book
Location
Dickson Building
Loan Period
3 weeks
Less detail

Colorectal Cancer : Evidence-Based Chemotherapy Strategies

https://libcat.nshealth.ca/en/permalink/provcat29815
edited by Maurie Markman, Leonard B. Saltz. --Totowa, NJ: Humana Press , c2007.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Markman, Maurie
Other Authors
Saltz, Leonard B
Responsibility
edited by Maurie Markman, Leonard B. Saltz
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2007
Series Title
Current clinical oncology
ISBN
9781597452151
Subjects (MeSH)
Colorectal Neoplasms - drug therapy
Antineoplastic Agents - therapeutic use
Subjects (LCSH)
Colorectal diseases
Oncology
Format
e-Book
Location
Online
Less detail

Combination Cancer Therapy : Modulators and Potentiators

https://libcat.nshealth.ca/en/permalink/provcat29068
edited by Gary K. Schwartz. --Totowa, NJ: Humana Press , c2005.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Schwartz, Gary K
Responsibility
edited by Gary K. Schwartz
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2005
Series Title
Cancer drug discovery and development
ISBN
9781592598649
Subjects (MeSH)
Drug Therapy, Combination
Neoplasms - drug therapy
Subjects (LCSH)
Oncology
Pharmacy
Format
e-Book
Location
Online
Less detail

Comfort care : palliative care symptom management : a guide for physicians

https://libcat.nshealth.ca/en/permalink/provcat20297
Phillips, W.G. Carlyle. --Halifax, NS: QEII Health Sciences Centre , 2000.
Call Number
QZ 267 P564 2000
Location
Dickson Building
Call Number
QZ 267 P564 2000
Author
Phillips, W.G. Carlyle
Place of Publication
Halifax, NS
Publisher
QEII Health Sciences Centre
Date of Publication
2000
ISBN
0968836704
Subjects (MeSH)
Palliative Care
Pain - drug therapy
Neoplasms - prevention & control
Neoplasms - drug therapy
Format
Book
Location
Dickson Building
Copies
1
Loan Period
3 weeks
Less detail

100 records – page 1 of 5.